论文部分内容阅读
目的观察大剂量重组人红细胞生成素(RHEpo)冲击治疗癌性贫血的疗效及副反应。方法 98例患者随机分入试验组或对照组。试验组采用大剂量RHEpo冲击法,对照组接受RHEpo常规剂量法。观察有效率、HbV、输血率及RHEpo不良反应。结果试验组治疗2周后HbV明显升高(P<0.01),对照组4周后HbV明显升高(P<0.01);试验组4、6周HbV高于对照组(P<0.05);试验组2、4、6周有效率为39.6%、58.3%、79.2%,高于对照组的17.0%、29.9%、51.1%(P<0.05,P<0.01);两组间输血率及药物不良反应率无明显差异。结论大剂量RHEpo冲击治疗癌性贫血的疗效优于常规剂量法,不良反应无增加。
Objective To observe the curative effect and side effects of high dose recombinant human erythropoietin (RHEpo) on cancer anemia. Methods 98 patients were randomly divided into experimental group or control group. The experimental group using high-dose RHEpo impact method, the control group received RHEpo conventional dose method. Observe the efficiency, HbV, blood transfusion and RHEpo adverse reactions. Results The HbV level in the experimental group was significantly increased after 2 weeks of treatment (P <0.01), and the HbV level in the control group was significantly increased after 4 weeks (P <0.01). HbV was higher in the experimental group at 4 and 6 weeks than in the control group (P <0.05) Group 2, 4, 6 weeks, the effective rate was 39.6%, 58.3%, 79.2%, higher than the control group of 17.0%, 29.9%, 51.1% (P 0. 05, P 0. 01); between the two groups transfusion rate and drug dysfunction No significant difference in response rate. Conclusion High dose of RHEpo shock treatment of cancer anemia better than the conventional dose method, no adverse reactions.